Balaxi Pharmaceuticals Limited (BALAXI) AI Stock Analysis

• Market Cap: ₹419.58M
• Dividend Yield: N/A
• Average Volume (3M): 75.37K
• Price to Earnings (P/E): 10.5
• Beta (1Y): 0.90
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 11,041,500
• 10 Day Avg. Volume: 158,740
• 30 Day Avg. Volume: 75,367
• PEG Ratio: -0.01
• Price to Book (P/B): 1.60
• Price to Sales (P/S): 1.28
• P/FCF Ratio: -6.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: ₹42.00 ▲(2.14% Upside)

Balaxi Pharmaceuticals' overall stock score is primarily influenced by its strong financial performance and attractive valuation. However, bearish technical indicators and cash flow concerns temper the outlook. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Strong Revenue Growth

Consistent revenue growth indicates a successful expansion strategy and strong market demand, enhancing the company's long-term prospects.

Solid Balance Sheet

A solid balance sheet with low leverage provides financial stability and flexibility, supporting sustainable growth and investment capacity.

Operational Efficiency

Strong margins demonstrate effective cost control and operational efficiency, which can drive profitability and competitive advantage.

Negative Factors

Inconsistent Net Income

Volatility in net income can indicate underlying operational challenges, impacting predictability and investor confidence.

Negative Cash Flow

Negative cash flow raises concerns about the company's ability to sustain operations without external financing, affecting long-term financial health.

Rising Debt Levels

Increased debt levels can strain financial resources and limit strategic flexibility, posing risks to long-term stability.

Balaxi Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Balaxi Ventures Ltd. engages in the wholesale trading of pharmaceuticals, food products, and hardware. The company is headquartered in Hyderabad, Telangana. The Company’s products include pharmaceuticals products, food products and builders’ hardware products. The company operates through the operating segment international wholesale trading. Its pharmaceutical formulations and builders’ hardware products are contract manufactured from manufacturing plants in India. The firm offers a range of food and biscuit products under the brand name YAP. Its subsidiaries include Balaxi Global DMCC.

How the Company Makes Money

Balaxi Pharmaceuticals generates revenue through multiple streams, including the sale of prescription medications, over-the-counter products, and specialty pharmaceuticals. The company partners with healthcare providers, pharmacies, and distributors to reach a broad customer base. Additionally, BALAXI may engage in licensing agreements with other pharmaceutical companies to develop or market specific drugs, which can provide significant income through royalties. The company also invests in research and development to create proprietary medications, enhancing its product portfolio and market competitiveness. Sales from both domestic and international markets contribute to its overall earnings.

Balaxi Pharmaceuticals Limited Financial Statement Overview

Summary

Balaxi Pharmaceuticals demonstrates strong revenue growth and a solid balance sheet with low leverage. However, inconsistent net income and negative cash flow in the latest fiscal year pose potential risks to financial health.

Income Statement

Balaxi Pharmaceuticals has shown a strong revenue growth trajectory, with a notable increase from 2024 to 2025. The gross profit and EBIT margins are solid, reflecting good cost management and operational efficiency. However, the net profit margin has been inconsistent, with significant fluctuations in net income, indicating potential volatility in earnings.

Balance Sheet

The company's balance sheet shows a healthy equity ratio, indicating a strong capital structure with significant stockholders' equity relative to total assets. The debt-to-equity ratio is low, which minimizes financial risk. However, there has been a substantial increase in total debt in 2025, which could suggest a higher financial leverage moving forward.

Cash Flow

Balaxi Pharmaceuticals has faced challenges with negative free cash flow in 2025, driven by a significant increase in capital expenditures and operating cash flow turning negative. This raises concerns about cash management and sustainability of operations without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.94B	2.89B	2.41B	3.36B	2.79B	2.31B
Gross Profit	1.25B	1.27B	1.13B	1.34B	837.91M	591.85M
EBITDA	264.46M	305.64M	456.59M	603.82M	560.20M	449.86M
Net Income	188.80M	250.70M	-23.87M	459.63M	476.58M	381.37M
Balance Sheet
Total Assets	0.00	3.10B	2.58B	2.40B	1.76B	996.80M
Cash, Cash Equivalents and Short-Term Investments	407.03M	394.00M	622.91M	282.17M	71.93M	16.69M
Total Debt	0.00	534.25M	194.04M	133.06M	36.38M	36.59M
Total Liabilities	-2.32B	786.06M	569.79M	567.89M	633.07M	347.00M
Stockholders Equity	2.32B	2.32B	2.01B	1.83B	1.13B	649.80M
Cash Flow
Free Cash Flow	0.00	-589.01M	32.97M	-89.05M	68.00M	-25.53M
Operating Cash Flow	0.00	-377.82M	48.66M	60.75M	341.44M	32.00K
Investing Cash Flow	0.00	-217.64M	-10.46M	-105.65M	-284.48M	-59.73M
Financing Cash Flow	0.00	366.55M	302.54M	255.13M	-1.63M	36.46M

Balaxi Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 41.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAXI, the sentiment is Negative. The current price of 41.12 is above the 20-day moving average (MA) of 39.36, below the 50-day MA of 41.97, and below the 200-day MA of 51.67, indicating a bearish trend. The MACD of -1.54 indicates Negative momentum. The RSI at 41.43 is Neutral, neither overbought nor oversold. The STOCH value of 37.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BALAXI.

Balaxi Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALAXI	62 Neutral	₹419.58M	10.47	―	―	―	―
BIOFILCHEM	55 Neutral	₹644.44M	23.02	―	―	36.76%	433.63%
INDSWFTLTD	53 Neutral	―	―	―	―	2.59%	1891.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LASA	43 Neutral	₹585.18M	-1.77	―	―	-20.40%	-59.20%
VIVIMEDLAB	37 Underperform	―	―	―	―	-22.42%	21.83%